Overview
Revenue
$10 to $25 million (USD) per year
Headquarters
Greater New York Area, East Coast, Northeastern US
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens. Champions Oncology, Inc. operates as a pharmaceutical company. The Company develops oncology drug products, as well as provides clinical solutions and trials. Champions Oncology serves patients worldwide. Champions Oncology develops advanced technology solutions and services for personalizing the development and use of oncology drugs. Learn about personalized cancer treatment and translational oncology research solutions that may help predict a patient’s clinical response to anticancer therapies through the use of mouse avatars.Champions Oncology was founded by some of the world’s most renowned specialists in the field of cancer diagnosis, treatment, and research. Our team is comprised of seasoned oncology professionals passionately dedicated to working with you to accelerate oncology drug development, improve outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar model for growing and testing human tumors. Champions Oncology (formerly Champions Biotechnology) is hoping to win big in the field of cancer research. Its Champions Tumorgraft platform allows the company to implant human tumors of various cancer types into mice, allowing scientists to study the effects of investigational drugs on human cancers. The company uses the platform in its own research and also provides tumor-specific research to doctors, as well as the Tumorgraft platform to other drug developers. The company has licensed the rights to explore Irinophore, a nanoparticle in preclinical development.
